Antigen-specific therapy for autoimmune disease

Current Opinion in Immunology

Volumn 12, Issue 6, 2000, Pages 704-711

  Harrison, Leonard C ^a   Hafler, David A ^b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; MYELIN; RETINA S ANTIGEN; THYROGLOBULIN;

APOPTOSIS; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CLONAL ANERGY; CYTOKINE PRODUCTION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HASHIMOTO DISEASE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; MUCOSA; MULTIPLE SCLEROSIS; NONHUMAN; RAT; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; T LYMPHOCYTE; UVEITIS;

EID: 0033738813     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00166-7     Document Type: Review

References (66)

1. Isolation of myelin basic protein-reactive T-cell lines from normal human blood
2. Multiple levels of peripheral tolerance
3. Oral tolerance: Mechanisms and therapeutic applications
4. Islet cell antigens in insulin-dependent diabetes: Pandora's box revisited
5. Systemic antigen in the treatment of T-cell mediated autoimmune diseases
6. Regulation of encephalitogenic T cells with recombinant TCR ligands
7. + T cells
8. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent
9. Systemic administration of agonist peptide blocks the progression of spontaneous CD8-mediated autoimmune diabetes in transgenic mice without bystander damage
10. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library
11. Specific vaccines against autoimmune diseases
12. Copolymer 1 inhibits experimental autoimmune uveoretinitis
13. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group
14. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: Quantitative MR assessment
15. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis
16. Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1
17. Oral tolerance in the treatment of inflammatory autoimmune diseases
18. Immunomodulation of experimental autoimmune diseases via oral tolerance
19. Peripheral deletion of antigen-reactive T cells in oral tolerance
20. Induction of rapid T cell activation and tolerance by systemic presentation of an orally administered antigen
21. Antigen-specific T cell activation and proliferation during oral tolerance induction
22. Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: A role for IL-10
23. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering
24. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis
25. Induction of oral tolerance to myelin basic protein in CD8-depleted mice: Both CD4+ and CD8+ cells mediate active suppression
26. Cytokine regulation of T-cell function: Potential for therapeutic intervention
27. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
28. Oral administration of myelin basic protein is superior to myelin in suppressing established relapsing experimental autoimmune encephalomyelitis
29. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes
30. Gamma delta T cells as mediators of mucosal tolerance: The autoimmune diabetes model
31. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23)
32. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes
33. Gamma/delta and other unconventional T lymphocytes: What do they see and what do they do?
34. CD8 T-cells are not essential for the induction of 'low-dose' oral tolerance
35. Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: Identification of regulatory cells
36. Lack of local suppression in orally tolerant CD8-deficient mice reveals a critical regulatory role of CD8+ T cells in the normal gut mucosa
37. Gamma delta T cells regulate mucosally induced tolerance in a dose-dependent fashion
38. Inductive events in oral tolerance in the TCR transgenic adoptive transfer model
39. Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells
40. Autoreactive CD4+ T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway
41. Impaired mucosal immune responses in interleukin 4-targeted mice
42. CD4+ but not CD8+ T cells are required for the induction of oral tolerance
43. IL-4 is a differentiation factor for transforming growth factor-beta secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis
44. Suppression of ongoing experimental allergic encephalomyelitis (EAE) in Lewis rats: Synergistic effects of myelin basic protein (MBP) peptide 68-86 and IL-4
45. IL-4 and IL-10 are both required for the induction of oral tolerance
46. Induction of oral tolerance in TGF-beta 1 null mice
47. Altered peptide ligand-induced partial T cell activation: Molecular mechanisms and role in T cell biology
48. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis
49. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens
50. IL-4, IL-10, IL-13, and TGF-beta from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis
51. Inhibition of naive class I-restricted T cells by altered peptide ligands
52. Changes in cytokine secretion induced by altered peptide ligands of myelin basic protein peptide 85.99
53. Cross-reactivity of T-cell clones specific for altered peptide ligands of myelin basic protein
54. Fine specificity of the myelinreactive T cell repertoire: Implications for TCR antagonism in autoimmunity
55. Antigen-specific immunomodulation confirms the encephalitogenic potential of myelin basic protein peptide (83-99) in multiple sclerosis
56. Coupling of peripheral tolerance to endogenous interleukin 10 promotes effective modulation of myelin-activated T cells and ameliorates experimental allergic encephalomyelitis
57. Antigen-specific signaling by a soluble, dimeric peptide/major histocompatibility complex class II/Fc chimera leading to T helper cell type 2 differentiation
58. An autoimmune disease with multiple molecular targets abrogated by the transgenic expression of a single autoantigen in the thymus
59. Transgenic expression of mouse proinsulin II prevents diabetes in non-obese diabetic mice
60. Transgenic expression of an immunologically privileged retinal antigen extraocularly enhances self tolerance and abrogates susceptibility to autoimmune uveitis
61. DNA immunization to prevent autoimmune diabetes
62. Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen
63. T cell design for therapy in autoimmune demyelinating disease
64. Late complications of immune deviation therapy in a nonhuman primate
65. Potential risk of oral insulin with adjuvant for the prevention of Type I diabetes: A protocol effective in NOD mice may exacerbate disease in BB rats
66. Induction of autoimmune diabetes by oral administration of autoantigen